Nicox

Ocumension Therapeutics announces completion of enrollment for OT-301 (NCX 470) phase III Denali trial in China, evaluating its safety and efficacy for IOP reduction in glaucoma and ocular hypertension patients.

Nicox secures $16.5M from Soleus via royalty sale and equity financing, funding until Q3 2025. Soleus buys Vyzulta royalties for $15M and invests $1.5M in Nicox shares. Nicox also agrees with main creditor for Vyzulta security release, repaying €5.2M by June 2025. NCX 470 Phase 3 trial recruitment accelerates, with first data expected in Q3 2025.

Nicox and Soleus Capital sign a $16.5 million royalty and equity financing deal, including $15 million for VYZULTA royalties and $1.5 million in Nicox shares with warrants. The transaction aims to finance Nicox into Q3 2025, repay €5.2 million of debt, and accelerate the NCX 470 Denali Phase 3 trial, with topline results expected in Q3 2025.

Regulatory snapshots: global drug submissions, approvals, clinical trial approvals, and other decisions involving Accord, Applied, Astrazeneca, Azitra, Briacell, Glycomine, Imcheck, Merck, Moderna, Nicox, Novartis, Valneva.

Nicox's partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular itching in China, adding a royalty revenue stream for Nicox. Ocumension forecasts peak sales over $100 million annually within 7 years.